Previous work on AD genetics has demonstrated the utility of grouping disease-associated variants into canonical pathways [13] [14] [15] [16] . However, manually curated pathways and scientific literature are incomplete, can lack disease specificity, and can reflect historical biases [17] [18] [19] . Network-based approaches (BOX 1) comprise complementary methods to identify the function of genetic variants and the basis of AD pathology, by mapping the genetic variants onto the interactions between the components of various biological systems 20, 21 . This framework facilitates the use of recent omics data sets and primary data from cohorts of individuals with AD to explore the effects of AD-associated genetic variants.
In this Review, we focus on how molecular networks provide a functional context for genetic risk variants in AD, and their potential for personalized diagnosis and disease stratification. We first consider ongoing efforts to identify genetic variants and current assessments of their role in AD pathology. Then, we examine network approaches to understand the function of AD variants, both at the molecular and the whole-brain neuroimaging level. Finally, we consider how multiscale models might bridge the gap between the effects of AD-associated variants at the molecular level and their function at the level of the brain, which could enhance the clinical relevance of genetic variants.
Genetic variants in Alzheimer disease -molecular and brain network approaches
Chris Gaiteri 1 , Sara Mostafavi 2 , Christopher J. Honey 3 , Philip L. De Jager 4 and David A. Bennett 1 Abstract | Genetic studies in late-onset Alzheimer disease (LOAD) are aimed at identifying core disease mechanisms and providing potential biomarkers and drug candidates to improve clinical care of AD. However, owing to the complexity of LOAD, including pathological heterogeneity and disease polygenicity, extraction of actionable guidance from LOAD genetics has been challenging. Past attempts to summarize the effects of LOAD-associated genetic variants have used pathway analysis and collections of small-scale experiments to hypothesize functional convergence across several variants. In this Review, we discuss how the study of molecular, cellular and brain networks provides additional information on the effects of LOAD-associated genetic variants. We then discuss emerging combinations of these omic data sets into multiscale models, which provide a more comprehensive representation of the effects of LOAD-associated genetic variants at multiple biophysical scales. Furthermore, we highlight the clinical potential of mechanistically coupling genetic variants and disease phenotypes with multiscale brain models.
Genetic variants
Insertion, deletion or alternative coding of DNA LOAD Late-onset Alzheimer disease (LOAD) is the most common form of the neurodegenerative disease, typically diagnosed clinically after the age of 65 years and definitively diagnosed postmortem. LOAD is associated with functionally diverse, weak genetic variants
Multiscale models
Mathematical or conceptual models that couple processes that occur on a varying range of physical or temporal scales, which are typically studied in isolation from each other
Amyloid hypothesis
Proposal according to which the root cause of Alzheimer disease is the accumulation of amyloid-β (Aβ), with nuances around sufficiency and form of amyloid-β responsible for pathogenesis
Amyloid precursor protein
Amyloid precursor protein (APP) is cleaved to form amyloid-β peptides. Presenilin (PSEN1 and PSEN2) mutations promote the cleavage of APP into plaque-forming peptides
Apolipoprotein E
Apolipoprotein E is a protein that physically interacts with amyloid-β (Aβ) and tau; its interaction with Aβ influences plaque aggregation. Dosage of the ε4 allele of the APOE gene is the strongest genetic risk factor for late-onset Alzheimer disease
Early genetic findings in AD The Aβ hypothesis and APOE variants Early genetic studies reported large effect sizes of genetic variants occurring in a group of genes that encode interacting proteins involved in Aβ processing. The resulting amyloid hypothesis profoundly influenced the direction of studies designed to prevent AD or modify the course of the disease 14, 22 . Although these findings have been applied to understanding LOAD, they were obtained in the context of familial AD (which is typically early-onset), with the discovery of mutations in the amyloid precursor protein (APP 23 ), presenilin-1 (PSEN1) and PSEN2 (REFS 24, 25) genes, and of relatively common AD-associated alleles of the apolipoprotein E (APOE) gene that can substantially increase the risk of LOAD 26 . The amyloid hypothesis has dominated the field for decades, and continues to be a major influence on clinical trials 27 . Several trials of Aβ modulators are ongoing. For example, the Alzheimer's Prevention Initiative launched two clinical trials to evaluate the effects of early antiamyloid treatment in populations at risk of AD -a large familial group in Columbia with early-onset AD driven by PSEN1 mutations 28 , and individuals homozygous for the APOE*ε4 allele. Similarly, the Dominantly Inherited Alzheimer Network (DIAN) study selected participants from approximately 500 families carrying dominant mutations in APP, PSEN1 or PSEN2, and is testing the effects of Aβ modulators 29 . Pioglitazone, a PPAR-γ agonist that is already approved and in widespread use for the treatment of type 2 diabetes, is also being tested for efficacy in preventing AD in people with specific APOE-TOMM40 haplotypes 30 . These trials, and many others, represent ongoing high levels of investment in the amyloid hypothesis.
Since the US government began tracking AD clinical trials consistently in 2002, more than 400 clinical trials have tested over 200 compounds 27 , of which only memantine produced a mild reduction in symptoms 31, 32 . Half of these trials involved Aβ-related therapies and failed to improve cognition in patients with AD, even when they significantly reduced Aβ levels [33] [34] [35] [36] . These results could have been expected given that after the onset of overt cognitive impairment, increasing Aβ levels are only weakly correlated with further impairment in cognitive function [37] [38] [39] . Thus, therapeutic intervention in the early stages of LOAD might be required for Aβ-targeted therapies to show efficacy, a concept that is currently being tested in individuals with mild cognitive impairment (MCI) 33 and high-risk asymptomatic participants 40 . It should be noted, however, that long-term administration of expensive agents, with potentially severe adverse effects, warrants careful ethical consideration, as AD-associated brain changes begin a decade or longer before AD-related cognitive decline 29, 41, 42 , and many individuals with moderate AD neuropathology do not have cognitive impairement 37, 43 . Regardless of the actual reason for the continued failure of trials that evaluate AD treatments, such lack of success is disconcerting in light of the large and increasing public health burden of the disease 7 . While these trials testify to the strength of the early findings on genetic perturbations of APP processing in AD, this approach is still strongly tied to scientific advances made three decades ago, as opposed to incorporating more-recent
Key points
• Genetic findings in late-onset Alzheimer disease (AD) have not yet resulted in strategies to prevent or treat AD • Examining the position of genes carrying disease-associated variants in large-scale molecular networks can aid identification of coherent disease mechanisms • Not all network approaches are equal: recent approaches involve networks that are directed (with causal links), and specific to the tissue and disease state • AD neuropathology and AD-associated genetic variants decrease efficiency of information transfer in the brain connectome, which can be quantified by measuring structural and functional patterns in brain networks • Construction of multiscale models of the effects of AD-associated genetic variants with large neuronal simulations is now feasible, and will be useful to understand the effects of such variants and to screen therapeutics in silico
Box 1 | Network-analysis approaches
Over the past decade, the term 'network analysis' has been used to refer to a variety of analytical approaches to analyse genomics data. By considering many relationships among biological entities simultaneously, network analyses shift the assumptions from one-to-one genotype-phenotype mapping to many-to-many mapping, which better accommodates the complexity of both the genetic basis and the phenotypic expression of chronic diseases. In this approach, networks (known as weighted graphs in computer science and mathematics) provide a generic framework to represent relationships or links between a set of entities -or units -which, in the context of genomic analysis can be molecules 53, 66, 219 , cells [220] [221] [222] [223] , tissues [224] [225] [226] or organisms [227] [228] [229] . Network-based approaches utilize one or more large knowledge sources to describe the functional relationships between units. These networks are most commonly utilized in the 'interpretation' phase of a genome-wide analysis to look for functional enrichment among the top hits. Increasingly, molecular networks have also been used during the discovery phase of genomic experiments (as with the NetWas approach 81 ) to identify novel genes or mechanisms associated with diseases. Two main sources of data can be used to construct gene networks: literature-curated interactions from low-throughput experiments, and high-throughput data sets that measure gene expression (and/or activity) across a large set of individuals or conditions. These two sources vary in terms of false-positive rates, coverage, prior knowledge, and context specificity. The meaning of a link in a molecular network can vary depending on the type of network: links can be physical links between molecules, represent signal transduction such as phosphorylation, or consist of statistical inferences derived from primary data, without specifying a particular mechanism of interaction, or involve unmeasured intermediaries. The connectivity in several types of networks has been used to provide context for Alzheimer disease variants (guilt by association) or to identify molecules and mechanisms associated with this condition.
PPAR-γ
Peroxisome proliferatoractivated receptor γ (PPAR-γ) is a component of a nuclear receptor complex that includes the retinoid X receptor. This complex is activated endogenously by fatty acids and leads to transcription of the apolipoprotein E gene, among other genes
Epistasis
When a combination of two or more genetic variants have a greater effect on a phenotype than their linear combination would predict
Pleiotropic effects
The contribution of a single gene, or variants of that gene, to two or more 'non-related' phenotypes genetic findings. It might be helpful, therefore, to use existing genetics findings and novel omics technologies to uncover the disease mechanisms of AD and identify novel therapeutic targets.
Genome-wide association studies
After the early work on variants in early-onset AD, genetic research shifted towards the identification of AD-associated variants that have weak effects or are very rare. To date, genome-wide association studies (GWAS) have identified more than 20 genetic variants that influence the risk of AD 12, 44, 45 . Although these studies have provided insights into possible pathophysiological mechanisms of AD 14, 15, 22 , AD-associated variants that are rare or that have a weak effect are challenging to use in prognosis 46, 47 , as their associated disease risk is lower than that of APOE variants, even when the variants are considered in aggregate 48 . These findings raise the question of how the identification of a wide range of variants can contribute to a coherent theory of AD pathology. In the past 2 years, whole-exome and targeted sequencing studies [49] [50] [51] have discovered rare variants that increase the risk of AD more strongly than do common variants (the odds ratios for certain TREM2 variants are on a par with those for APOE*ε4 variants, for example).
Ongoing whole-genome sequencing projects, such as the Alzheimer's Disease Sequencing Project, will continue to identify susceptibility loci in AD; however, the overall scientific returns of hunting for genetic variants are diminishing relative to the increasing size of the projects 52 . Gaining insight into the multigenic and multifactorial disease mechanisms in AD requires methods that go well beyond simple genotype-phenotype models. We must now start to scientifically consider and understand many genes, many phenotypes, and the interactions between them. This nascent third stage of AD genetics, the main focus of this Review, uses systems biology methods that emphasize how variants interact and how their effects propagate through networks of molecular and brain circuit interactions, which span biophysical scales.
Molecular interactions in AD Epistatic regulation in AD
The effects of interactions between genetic variants might help explain the gap between the high heritability of AD and the weak effects of genetic variants 48 . Epistasis, which can consist of synergistic or dyssynergistic genegene interactions, is the simplest form of multigene interaction, and is related to phenotypes 53, 54 or disease status [55] [56] [57] . As described below, the combinatorial nature of epistasis might be useful in accounting for the personalized molecular basis for AD risk in a given patient 58 . Incorporation of epistatic interactions to understand AD heritability provides a direct connection between traditional additive genetics (GWAS) and the largescale molecular-interaction networks described in the sections that follow.
Early attempts to find epistasis in AD were largely hypothesis-driven, and only a minority of the proposed epistatic interactions were replicated 59 . Given the large burden associated with multiple testing and the large sample size necessary to detect genetic interactions, most studies have been focused on detecting interactions between marginally associated variants, and mainly found effects between such variants and APOE haplotypes 60 . However, certain gene-gene interactions can be associated with AD even if neither locus is independently associated with the disease 61, 62 . Considering all possible combinations of variants produces a high multiple testing burden, which is magnified when examining multiple phenotypes, such as the volume of multiple brain regions. Therefore, some studies have opted for a middle ground: epistasis testing was limited to pairs of genes in the same functional pathways, and epistasis was found for hippocampal atrophy 63 and temporal lobe volume 64 .
Edgetic effects
Genetic variations that alter the affinity of specific protein-protein interactions (the edges between proteins in a network diagram), as opposed to all the interactions of a given protein, are referred to as 'edgetic effects' (REF. 65 ). Edgetic interactions are based on protein-protein binding information, in contrast to the epistatic interactions mentioned above, which are primarily statistical interactions, the physical basis of which might be unclear. Edgetic alterations resulting from genetic variants can be identified experimentally or predicted by high-resolution 3D models of protein structure and protein-protein interactions 66 (FIG. 1a) . This concept is helpful to associate specific alterations in protein interactions with disease states. For example, pleiotropic effects can sometimes be explained by alterations of distinct protein interfaces of a single protein: each interface affects distinct partners and triggers distinct phenotypes 67 . In the context of Mendelian disorders, disease-associated genetic variants are likely to result in edgetic effects 68 . Whether this edgetic framework can be applied to study the effects of AD genetic variants is unclear.
Targeted sequencing or exome sequencing efforts carried out in the past few years have identified coding variants in ABCA7, ADAM10, BIN1, CD2AP, CLU, CR1, EPHA1, MS4A4A/MS4A6A, PICALM, PLD3, SORL1 and TREM2 that are associated with late-onset AD 49, 50, 69, 70 , in addition to the familial AD variants in PSEN1/2 and APP. Thus, it is likely that, as whole-genome sequencing becomes more common, person-specific coding variants might also be mapped edgetically to generate detailed individual molecular networks -a process that is already possible for several thousand proteins with known structures 66 (FIG. 1a) .
Network-based approaches to AD genetics Aggregating a collection of epistatic or edgetic interactions to identify specific disease mechanisms is still challenging, owing to missing information about how such interactions affect specific cellular systems or neuronal activity. Alternative network-based approaches
leverage large-scale molecular networks to help identify coherent biological functions. The structure of these molecular networks contains information that is useful to determine the function of biological systems. For instance, molecules involved in a particular biological function tend to be densely and mutually connected [71] [72] [73] [74] . Network approaches are different from pathway analysis: they can provide tissue-specific and disease-specific information from the latest omic technologies, and are not limited by the state of knowledge about canonical pathways (FIG. 1b) . In some cases, network-based approaches intersect with the study of AD-associated genetic variants, but we also review select cases outside the AD context that involve principles or practical approaches that could be useful in characterizing the function of AD variants.
Coexpression networks
Coexpression-based networks
FIG. 1a,c) are a common type of data-driven network, in which links represent the strength of gene-gene correlations. These links between genes can be generated by many mechanisms, including microRNAs, cell-type specificity, chromosome conformation, epigenetics and cell-type proportions, that regulate gene expression 21 . Correlation links between genes are, therefore, useful in the context of disease: clusters of coexpressed genes can be a proxy for alterations in gene expression regulatory mechanisms, and the levels of coexpressed genes can be matched to disease phenotypes to prioritize certain molecular systems for follow-up experiments. Advantages of the coexpression-analysis approach include their coherence with genetic findings, potential tissue specificity, and greater robustness in comparison with univariate or single-gene approaches.
Genetic integration. Genetic variants that interact in protein-protein interaction (PPI) networks
and tend to be coexpressed have been identified in AD 75 , autism 76 and schizophrenia 77 . In individuals with autism, the coherence between coexpression and PPIs has been used to filter for molecular systems that show enrichment in de novo mutations 78 .
Tissue specificity. Obtaining tissue-specificity and building coexpression networks in tissues relevant to disease can be crucial for the identification of relevant and accurate coexpression networks in neurological disorders [79] [80] [81] . The Genotype-Tissue Expression project (GTEx) consortium was created to make tissue-specific data more accessible by generating transcriptomic profiles of a large number of human tissues, with plans to examine the genetic effects of the tissue context 82, 83 .
Robustness. Patterns of gene coexpression in the CA1
and CA3 regions of the human hippocampus were compared with disease progression and pathology to prioritize disease-associated molecular systems 84 . These coexpression clusters were identified without using genetic information per se; however, they showed coherence with subsequent coexpression, genetic and experimental studies, with regard to the TYROBP-TREM2 signalling cascade 85, 86 .
Network-based stratification
Network-based patient stratification, an approach utilized in oncology, provides a clear example of how molecular interaction networks can aggregate diverse genetic effects to uncover disease mechanisms that are relevant to personalized treatment 87 . Briefly, genes carrying disease-linked variants were located in publically available PPI networks
. Variants carried by patients with similar prognoses were mostly found in genes that were located in certain areas of the PPI network 87 . Thus, the PPI network can be used to stratify patients and to highlight candidate disease mechanisms that involve molecules in the affected area of the network. Drug-target interactions can also be included in these networks to enhance their clinical utility: such networks would enable the identification of drugs that target the specific regions of a network that are affected in a particular person 88 . In AD, the effects of individual genetic variants are relatively small, and network-based stratification is an example of how genetic variation can be aggregated in a clinically relevant manner. Application of this tool to large cancer cohorts 89 has provided a roadmap for how molecular networks could be helpful in identifying personalized mechanisms of AD, especially as whole-genome sequencing becomes commonplace. Similar approaches have been utilized in schizophrenia 77 and autism 76 to find network regions that are enriched with disease-associated mutations, although such approaches have yet to be applied to AD.
Analysis of directed networks
To estimate the effects of disease-associated variants, the studies cited thus far utilized undirected networks, such 
Directed networks
Networks where elements are connected by links with a specific direction that represents an asymmetric temporal or transfer function as coexpression networks or PPIs, in which elements are connected by links without specific direction that would imply causality. Combining the genetic analysis of pathological variants with gene expression data provides a causal basis for expression changes, which can be used to infer directed networks 90 . Previously, the use of directed networks required large computing clusters, but the CINDERellA project has enabled researchers to infer disease-specific directed networks using standard hardware 91 . A previous generation of the directed/causal network approach was applied to microarray and single nucleotide polymorphism (SNP) data obtained from prefrontal cortex tissue samples from 173 healthy individuals and 376 individuals with AD 85 . This approach, which included the analysis of expression quantitative trait loci (eQTLs), implicated TYROBP (which encodes part of a microglial membrane receptor complex) as an upstream node in an AD-associated network of several hundred genes related to multiple immune subsystems, including CD33, MS4A4A, MS4A6A and TREM2, which were previously identified as AD susceptibility genes by GWAS.
Disease state-specific networks
Many network studies were carried out with the assumption that networks generated from data sets in control/ healthy systems are sufficiently similar to networks found in the disease state; however, pathological processes or responses to disease can alter network structure. For example, certain gene-gene correlations might only be observed in disease-state data (differential coexpression) 92, 93 . Traditional differential expression analysis might not detect cases of differential coexpression, because gene-gene correlations can be altered without changes in the average expression level of the two genes 21 . Differential coexpression was observed between several molecular systems when control and AD gene expression patterns were compared 85, 94 , and between PSEN1 and groups of genes highly expressed in oligodendrocyte and microglia when mouse and human coexpression patterns were compared 95 . However, collecting samples of 'true' control-state or disease-state networks is challenging, as the phenotypic variability in AD is a continuum and AD pathology can be present long before the onset of clinical signs and symptoms 96 . A hybrid approach, which requires the presence of both clinical and pathological manifestations of the disease to establish an AD diagnosis, might lead to loss of information on the unique molecular basis of the different -but related -phenotypic aspects of AD 97 .
Neuropathological studies of AD variants
A fundamental assumption of AD case-control GWAS is that individuals can be meaningfully classified according to observable clinical behaviour and accepted definitions of the disease. However, many individuals who are classified as 'cognitively normal' harbour AD pathology, infarcts and Lewy bodies 98 , and many individuals who are clinically diagnosed with AD are affected by other pathologies 99 
. This inaccuracy in disease status and the many comorbid (yet typically unmeasured) conditions that are present in older populations reduces statistical power and places practical limits on the effectiveness of case-control studies of AD. By conducting GWAS on AD endophenotypes (such as neuropathological and neuroimaging features), it is possible to reduce the effects of confounding factors associated with subclinical disease and comorbid conditions, and to increase statistical power with quantitative outcomes 100 . The ultimate goal of this approach is to compile these partially overlapping genetic signatures into a more robust description of AD.
Collecting neuropathological data is onerous, but such efforts are leading to the identification of novel loci associated with different types of AD and their related neuropathological features 97, 101 . GWAS on common age-related neurodegenerative disorders, such as hippocampal sclerosis and cerebral amyloid angiopathy, have identified loci involved in each pathology, half of which are also found via case-control AD 
Clustering coefficient
Measure of modularity around a network node. The coefficient represents the number of connections among neighbours of a node divided by the maximum possible number of connections among those neighbours GWAS 97 . Combining genetic data with detailed neuropathological phenotypes has the advantage of placing the genetic variants in the context of a particular pathophysiological process. Moreover, this approach has identified loci that are not found by traditional GWAS, and that contribute to pathologies associated with AD dementia.
Insights from AD network neuroimaging Genetic factors shape brain structure, connectivity and function 102 . Alterations in various brain regions have been linked to AD 103 , with canonical sites of early AD-associated effects in the hippocampal region 104, 105 . To understand how AD affects macroscopic brain structures and brain dynamics on a global scale that is relevant to cognitive functions, some neuroimaging efforts have adopted a network-based approach [106] [107] [108] . This work is based on the observation that the networks of the healthy brain must simultaneously achieve two objectives, which can appear to be opposed. On the one hand, brain networks must support functional specialization, which requires some isolated modules or clusters; on the other hand, brain networks must support coordination and information flow between diverse systems, which requires the existence of short-cut paths between modules 109, 110 . Healthy brain networks generally exhibit a balance of high modularity (locality) and short path lengths (integration) to support perceptual and cognitive processing 106, 108, 111, 112 . In the field of network neuroimaging, AD pathogenesis has been characterized as an imbalance between modular and integrative processes.
Balancing local and global functions
When a network simultaneously supports modular function (local clusters) as well as integration (a short average path length between nodes), it is said to have small-world organization 113 (FIG. 1d) . The extent of smallworld organization in brain networks is heritable 114, 115 , and predictive of AD status 116, 117 and progression 118 . Moreover, changes to the small-world balance can be detected before neurodegeneration or cognitive decline in people with elevated brain amyloid levels 119 . In AD, changes in small-world organization can arise from changes in the shortest average path between nodes and/or changes to the clustering coefficient 120, 121 (FIG. 1d) .
These changes, which may be due to amyloid accumulation in the hub regions of the brain 122 , can be visualized with several imaging methods, including functional MRI (fMRI) 120, 123 , magnetoencephalography 124 , EEG 123 and structural imaging 121, 125 . Importantly, although the presence of short paths in networks has been associated with cognitive function in healthy cohorts 111, 126 , specific cognitive deficits in AD have not been conclusively linked to this metric. Cohort studies have shown that the alteration of brain networks in MCI is generally less severe than in AD 117 ; however, some individuals with MCI can show selectively increased connectivity as a potential compensatory mechanism 123, 127, 128 (FIG. 1d) .
Critical nodes: hubs and rich clubs
Brain region connectivity has implications for the localization and propagation of AD pathology. For instance, 'hubs' are regions with many connections to other regions, and changes in hubs are implicated in multiple brain disorders 129 . Hubs are preferentially affected in AD, potentially owing to unique metabolic demands or cellular processes in these regions 130, 131 . A large study, which included patients with MCI or AD, showed decreased global integration and decreased interconnections mediated by hubs within the default mode network (DMN) 132 (FIG. 1d) . Brain hubs that are densely coupled to each other are termed a 'rich club' (REF. 133 ). Damage to rich club nodes could be especially disruptive to brain function, as they are the intersection points for many paths that link distal regions 134 . Consistent with this hypothesis, the connectivity of rich club nodes is affected in APOE*ε4 carriers 135 , and alterations of hub connectivity are correlated with cognitive performance in patients with AD 136 . However, connectivity of rich club brain regions could be more strongly altered in early-onset AD and frontotemporal dementia than in LOAD 137, 138 .
Network changes linked to AD genetics
Global and local brain network changes are associated with an AD diagnosis, but few studies have examined the effects of AD-associated genomic variants on brain networks independently of diagnosis. Most of the studies focusing on APOE*ε4 carriers versus non-carriers have found alterations of the DMN [139] [140] [141] , and of the small-world integration-modularity balance 142 , with studies of all APOE alleles pointing towards additional subnetworks, the activation of which is influenced by genetics 143 . These changes take place years before the onset of AD 139 , are stable through midlife 144 , and might be associated with decreased connectivity and metabolism in the DMN in AD [145] [146] [147] . Similar effects on the DMN are seen in the form of familial AD that results
Box 3 | Cognitive ability and reserve
Baseline cognitive function and decline in cognitive function in individuals without dementia are affected by genetics 234, 235 , several neuropathologies 96 , and lifestyle factors, such as social 236 and physical 237 activity and lifelong cognitive activity 238, 239 . Similarly, in the population with Alzheimer disease (AD), the level of cognitive function is influenced by lifestyle factors including education and occupation 240, 241 , and disease-related decline 242 . However, classic AD pathology explains less than one-third of the variance of cognitive decline 38 . Furthermore, many individuals presenting with AD neuropathology maintain adequate cognitive function 37, 98 . The concept of cognitive reserve has been proposed to help explain the discrepancy between predicted and actual cognitive decline 241, 243 . This disconnection between pathological indices and cognitive function is a strong motivation to study the genetic basis of cognitive function and cognitive decline seen in AD.
High cognitive function in midlife can be considered a component of cognitive reserve, as it can delay AD diagnosis 244, 245 . Twin studies indicate that cognitive functions have a substantial genetic component 246 . For example, of 13 single nucleotide polymorphisms associated with general cognitive function, four (TOMM40, APOE, MEF2C and ABCG1) have been consistently implicated in AD 247 , and others were associated with the rate of cognitive decline (CR1) 248 , episodic memory (PICALM) 249 and working memory performance tasks (BIN1) 250 . The most consistent finding by far was the association of APOE with various cognitive phenotypes and the rate of decline in cognitive function with age 251, 252 . However, some of this overlap in the genetic bases of cognitive function and AD-associated dementia might be due to the fact that decline in cognitive ability can occur naturally with time or with AD.
from mutations in genes involved in Aβ processing 148 . Although an AD-associated CLU variant has also been shown to correlate with brain structural path lengths in healthy individuals 149 , most genetic studies on brain networks in AD have focused on APOE, rather than other recent AD GWAS hits. It is unclear whether this is due to historical effects or reflects truly larger effects of APOE alleles on brain network structure.
Challenges and next steps
As mentioned above, an imbalance of modularity and integration is regularly reported in individuals with AD. However, the features that drive the imbalance varies across studies and methods. Many (but not all [150] [151] [152] ) imaging studies -in particular, those that measured structural connectivity networks-have found increased path length in AD brain networks 120, 121, [153] [154] [155] [156] . By contrast, the other component of small-world networks, the clustering coefficient, was decreased in AD in some studies 124, 150, 151, 157, 158 , but increased in others 125, 156, 159 . Differences in imaging modalities, network connectivity normalization in the context of neurodegeneration, and/or intrinsic limitations of the resting-state paradigm might be responsible for this range of results.
Although inferred functional brain networks are constrained by underlying structural connections 160 , the correspondence of structural and functional networks is not straightforward 161 , and not all networks should be expected to show identical effects in AD. This confounding factor is exacerbated by variations in cohort characteristics, and by the effects of haemodynamics and arousal, which are difficult to control in clinical neuroimaging settings 162, 163 . Guidelines are emerging for optimal data preprocessing 164 , which should improve the consistency and replicability of network characterizations in AD. Neuroimaging studies sometimes treat brain networks as if they were static; however, dynamic functional connectivity studies suggest that resting-state networks are a blurred representation of transiently activated regional subnetworks 106, [165] [166] [167] . Consideration of these network fluctuations in disease states [168] [169] [170] may resolve discrepancies among studies that have assumed a constant network architecture 170 . To truly characterize the multiscale processes that are affected in AD, it is crucial to develop network signatures that go beyond the measurement of the small-world balance 171 . This can be done by identifying specific network systems (for example, configurations of DMN interactions) that are associated with functions (for example, spatial episodic memory) that can be behaviourally assayed in individuals at risk of AD. This way, the 'function' of a particular functional network can be connected more directly to a behavioural phenotype of AD. Finally, as we discuss in the next section, it is crucial that the next generation of network signatures are derived from biologically constrained multiscale models of AD pathology.
Multiscale models of AD
To date, studies have typically examined the effects of AD genetics on molecular networks (FIG. 1a) or on largescale brain networks (FIG. 1d) . These two perspectives are missing a description of how the molecular effects of AD-associated variants translate into structural brain changes, which in turn can represent cognitive decline in AD. Describing how molecular and brain networks are mechanistically coupled together might help to reduce false positives in drug development, as the molecular assays to test drugs could be linked to brain activity measures that are closer to clinical-level effects. Similarly, brain connectivity and neuroimaging findings are generally described in a manner that is uncoupled from molecular activity. Coupling of brain connectivity to molecular properties provides an experimentally tractable basis to address changes in disease.
Multiscale models help to fill the gap between the effects of genetic variants on molecular networks and brain networks 172, 173 . These models go beyond typical imaging-genetics approaches, and can be useful in identifying which molecular and cellular features have an effect on a given tissue or have clinical-level properties, such as patterns of fMRI connectivity that are associated with cognitive function. A concrete example of a neuronal property that could be well represented by multiscale models is long-term potentiation (LTP) of synapses, which is triggered by coincident presynaptic input and large postsynaptic depolarization. Initiation of LTP is rapid, but the gene expression, translation and cytoskeletal rearrangement that this process entails are relatively slow. In the context of AD, a multiscale model could include the experimentally observed effects of AD-associated variants on cellular processes (for example, the effects of amyloid on LTP), which are then 'scaled up' into larger and more realistic brain networks through computational simulations [174] [175] [176] [177] (FIG. 2) .
Potential to complement AD research
Multiscale models are particularly important for AD because the effects of the disease on executive control and memory can be plausibly captured by whole-brain models 108, 178 , whereas therapies are generally developed at the molecular level. These models have the potential to rapidly identify specific molecular properties that exert the strongest effects on the clinical read-out [179] [180] [181] ; thus, they are valuable in silico tools to understand drug mechanisms of action and to evaluate the molecular systems affected by an individual's genetics. The potential use of multiscale models should not be perceived as a replacement for experimental work; rather, it is a way of aggregating and extracting the implications of experimental results. Such models are necessary given the diverse systems involved in AD pathology, its decades-long prodrome, and the lack of sufficiently predictive animal models [182] [183] [184] . At present, network models of AD typically operate on a single physical scale, and they ignore other spatial scales and the temporal component entirely 185 . Whereas multiscale models are rapidly developing in other areas of neuroscience 179, [186] [187] [188] [189] , they are only just starting to be utilized in AD 190 . Therefore, we examine below how multiscale modelling in other diseases and biological systems can enable realistic and rapid examination of the effect of AD genetic variants, in a way that is useful for clinical progress. In particular, two bridges between scales -gene-electrophysiology coupling and neuron-tissue coupling -are likely to be essential for multiscale models of AD to become useful in a preclinical setting.
Gene expression and neuronal activity
Both gene expression and electrophysiology studies have a strong influence on AD research. Integration of these approaches into a multiscale model would have conceptual and practical benefits for the development of AD therapeutics, as cell membranes are very accessible to drugs, can be mathematically modelled in great detail, and are essential to brain function. Few studies have described the feedback between gene expression and electrophysiology in a manner than enables predictive multiscale models of AD. Nonetheless, a study of the suprachiasmatic nucleus 191 exemplified the potential of combining gene expression and neuronal activity into a unified multiscale model, which can be used to simulate neuronal activity under many different physiological conditions. The cellular aspects included in the simulations span a range of temporal and physical scales, including (from smallest to largest) intracellular calcium levels, circadian gene expression, ion channels, intracellular neuropeptides, and synaptic connectivity. All of these components of the model were mathematically coupled with interacting differential equations to represent the relationships observed experimentally. This simulation was helpful for reconciling long-standing experimental differences observed between results obtained in various laboratories on the effects of γ-amino butyric acid on suprachiasmatic nucleus activity. This example illustrates the complete life cycle of multiscale models: the association of gene expression to systems-level phenomena, such as neurotransmission and circadian activity, resulting in testable hypotheses that are examined experimentally 192 . Increased use of CRISPR-Cas9-based genome editing, optigenetics, and single-cell RNAseq or ATACseq will facilitate experiments to simultaneously measure relationships between gene expression and electrophysiological activity in closely controlled systems. Such experiments are prime sources for the components of multiscale gene-electrophysiology models applicable to AD.
Neuron-tissue coupling
In the process of scaling the effect of genetic variants to the level of whole-brain activity, a second major bridge across physiological scales is between single neuron properties and large-scale networks that model the activity of millions of neurons [193] [194] [195] . Simulations of large-scale networks can include different excitatory and inhibitory cell types, with their respective ion channel conductances, connected with realistic columnar and inter-regional patterns (FIG. 2b) . Far more information is available to generate this aspect of the multiscale model than is available to model the effects of genetic variants. A key challenge, therefore, is to determine the useful level of biological detail in simulations 195 . Simulated neuronal activity can be linked to brain imaging studies by pooling the activity of groups of neurons to represent different brain regions 193 (FIG. 2c) . Such whole-brain networks show dynamic response patterns that are associated with perceptual and memory processes, and are helpful to understand the interplay between chemical, structural and functional aspects of neurological diseases, as demonstrated in recent multiscale models of schizophrenia 196 . Although these models cannot yet be used to model the effects of genetic variants, they already contain downstream components of genetic effects, such as intracellular components, detailed neuronal morphology and connectivity, which, together, reproduce fMRI features associated with memory 197 and cognition 178 . As such multiscale models begin to incorporate disease-specific effects, including genetics, they will become useful in silico screening tools for AD cellular interventions.
Roadmap to multiscale models of AD Here, we specify the components of one of the possible multiscale models of AD and provide one possible roadmap (FIG. 2) for scaling the effects of AD genetic variants up to the level of whole-brain models 194, [198] [199] [200] . First, the effects of AD-associated variants on the electrophysiological and morphological features of neurons (directly or via other cell types) can be assessed either by changes in ion channel populations or by fitting the observed electrophysiological recordings to mathematical models of neuronal activity 201 (FIG. 2a) . This strategy is helpful for bypassing some details of the intracellular signalling that transduces the effects of variants to membrane properties. In the second stage of multiscale modelling, the spiking and network activity of models with and without genetic variants (FIG. 2b) can be connected to each other with the desired level of detail, mainly limited by computational power. In sufficiently large numbers or with approximations of the average activity of large numbers of neurons, these computational models can generate a reasonable approximation of the whole-brain dynamics observed in resting-state fMRI studies 193 (FIG. 2c) .
Practical challenges
Challenges in the implementation of multiscale models that incorporate the effects of AD-associated genetic variants include the difficulty of identifying the exact location of the relevant variant, which can often fall in a noncoding region 202 , and the fact that some AD-associated genetic variants, particularly those that affect non-neuronal cell types, may not have known synaptic effects. Analysis of epigenetic information can narrow the size of the relevant locus 203, 204 . The epigenetic resources to localize AD-associated variants are limited, but they are rapidly expanding 205, 206 and becoming more relevant to brain cell types 207 . The effects of noncoding AD-associated variants can be assessed by creating cell lines each with a mutation in a different subregion of the locus, and evaluating the effects of these mutations in electrophysiological and cell imaging experiments. Effects observed in these experiments can be included Comparison to fMRI and EEG data for validation Filtered and smoothed population activity in neuronal models of disease and compared with output of control-state models, or with the effects of other variants. Regarding variants that affect non-neuronal cell types, the effects of such cell types on neurons can be included in neuronal simulations. For example, certain TREM2 variants are associated with AD, and activation of TREM2 signalling in microglia can lead to decreased neurite length. Such effects can be included neuronal models, which are, in turn, components of whole-brain models.
Conceptual challenges
Ambitious modelling projects, such as multiscale modelling of the effects of disease-associated variants (FIG. 2) , are sometimes dismissed because genes, cells and brain networks have important properties that are not yet measured and can lead to variable results 208 . Indeed, the absence of constraining data is a challenge for modelling efforts in many domains of biology, and has no easy solution. However large-scale and multiscale models have yielded useful insights in several areas of biology, including whole-cell modelling 209 , cancer 176 , cardiology 175, 177 , immunology 174 and neuroscience 189, 191, 210, 211 . Moreover, the data required to constrain multiscale models is rapidly accumulating as part of the data-heavy, multicontinental collaboration initiatives led by private and public funders [212] [213] [214] , such as the large-scale coordination of open science for target discovery in the Accelerating Medicines Partnership for Alzheimer Disease (AMP-AD). A particular advantage of multiscale models is that they remain constrained by a large set of results (FIG. 2) ; for example, macroscopic data, such as population electrophysiology measures or fMRI data, can provide additional constraints on microscopic parameters, such as membrane conductances, by comparing the output of the model in 'healthy' and 'disease' states with actual healthy fMRI, EEG or magnetoencephalography results. Finally, we emphasize that these models do not attempt to copy the brain in all of its complexity. The goal is to simplify the real system, so as to distill some of its core functions with sufficient accuracy to predict the behaviour of the real system in some limited setting 195, 215 . In this light, multiscale modelling is simply a more quantitative and systematic approach to the general scientific endeavour, and one that explicitly couples different experimental programmes rather than leaving their interaction to chance.
Conclusions
The past decade of AD genetic discoveries has been marked by the search for coherence among diseaseassociated variants with weak effects and functional diversity. Concurrently, omic technologies and neuroimaging have produced detailed descriptions of molecular and brain networks. These trends of diverse genetic findings and biological networks are converging in studies of large AD cohorts, which shed light on the functional roles of AD-associated variants and point towards convergent functions of such variants. At the molecular level, several types of molecular interactions, including epistasis, protein-protein interactions and gene coexpression, define the intricate relationships between variants and genome-wide molecular systems. Measurements of differential coexpression and edgetic changes enable the identification of networks that only exist in the disease state, and these novel interaction structures may be crucial for understanding pathogenesis. The effects of individual and combinations of AD-associated genetic variants can also be observed on structural and functional brain connectivity patterns. These effects show that some variants affect the integration-segregation balance of brain networks, which is critical for perceptual and cognitive function. However, identifying how variants alter brain connectivity patterns entails understanding their effects on cell morphology and electrophysiology, and creating integrated multiscale models to capture their full effects on brain microcircuits and regional connectivity.
Although molecular and brain networks are the most complete description of the biological processes altered in patients with AD to date, they are still incomplete and potentially biased, and they represent a static picture of the disease. Advancing to the point where network tools can generate a dynamic, multiscale description of AD that is sufficiently accurate to provide personalized diagnosis or screen potential therapeutic targets involves challenges in computational infrastructure, omics data acquisition and the social organization of science. Specifically, construction of multiscale models requires openness and novel collaborations among groups of investigators, breaking out from traditional academic boundaries, to become more aligned with patterns of molecular interactions 216, 217 . Though daunting, such coordination between researchers is possible, as demonstrated by the centralized efforts to annotate genome-wide metabolic networks and the openscience enterprise of the AMP-AD Target Discovery and Preclinical Validation Project 218 . The resulting patterns of activity can be fitted to mathematical neuronal models -the building blocks of larger microcircuits and brain region models. b | Connectivity between and within brain regions, such as different cortical layers (L1, L2/3, L4) and other structures, including components of the thalamus (nucleus reticularis thalami (nRT), thalamic core (COR), thalamic matrix (MTX)) can be extracted from human and other primate brain tissue (top left). This information can be combined with cellular parameters, such as cell morphology and connectivity, that can be measured by electron microscopy (EM), and inter-regional parameters that can be measured by diffusion spectrum imaging (DSI), to generate detailed realistic connectivity matrices (top right). Such matrices establish a synaptic connection among dynamic neuron models (a), from which spontaneous or evoked activity can be simulated (spike raster plots at the bottom). The effects of AD variants on network activity can be observed by comparing neuronal network models that do or do not incorporate the effects of AD variants. c | The model activity in various brain regions, with or without AD variants, can be temporally smoothed to provide an output analogous to functional MRI (fMRI) data, which can then be compared with published studies. The actions of various drugs or molecular interventions can also quickly be examined at this level -a level much closer to a cognitive phenotype -which may be helpful in screening potential therapies. iPSC, induced pluripotent stem cell.
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